HAVN Life Sciences Inc Ordinary Shares HAVLF
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.01 / $0.11
- Shares Outstanding
- 14.74M
- Market Cap
- $14.74
- Volume/Avg
- 166 / 2,284
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
HAVN Life Sciences Inc is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and therapies to support brain health and enhance the capabilities of the mind. Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, it offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 6
- Website
- https://www.havnlife.com
Valuation
|
Metric
|
HAVLF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HAVLF
|
|---|---|
Quick Ratio | 0.60 |
Current Ratio | 2.68 |
Interest Coverage | −1,030.99 |
Quick Ratio
HAVLF
Profitability
|
Metric
|
HAVLF
|
|---|---|
Return on Assets (Normalized) | −102.81% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −116.98% |
Return on Assets
HAVLF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#p<%@Tq | LOCK|#pFh | $128B | |||
| Moderna Inc
MRNA
| LOCK|B%zlPJR | LOCK|%R | $81B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<^N<!%? | LOCK|F?pMW | $75B | |||
| argenx SE ADR
ARGX
| LOCK|#>Q#rS& | LOCK|$rK | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<>PPPZ | LOCK|F& | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|b@rN&D | LOCK|?KMC | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|sBQLrHH | LOCK|^Wv& | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|%Q&<$@ | LOCK|@! | $25B | |||
| Incyte Corp
INCY
| LOCK|Q?nkx@ | LOCK|xLN | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!NwJf&W | LOCK|N^N | $15B |
United States